| MUC1 is a large glycoprotein that is expressed on ductal epithelial cells and also the majority of epithelial adenocarcinomas. Dysregulated expression of aberrantly glycoslyated MUC1 in carcinomas allows tumor-specific recognition of MUC1-derived epitopes by antibodies and T lymphocytes. However, despite the ability of CTL to specifically recognize and kill MUC1 + tumor cells, immune responses in cancer patients fail to prevent tumor progression. The failure of patients' immune systems to eradicate MUC1 + tumors has been linked with their inability to mount MUC1-specific helper T cell responses.; Here we show that CD4+ T cells play a central role in both the enhancement and suppression of MUC1-specific immune responses. Using MUC1-Tg mice as a model for tolerance to self-expressed MUC1, we show that MUC1-specific regulatory T cells (Tregs) respond to stimulation with MUC1 in the absence of a CD4+ T helper response. The Treg:Th imbalance in MUC1-Tg mice causes the suppression of MUC1-specific immunity. This suppression can be overcome by providing functional Th cells from WT mice. To focus our studies on MUC1-specific CD4+ T cells, we created a TCR-transgenic mouse whose CD4+ T cells are specific for an MHC Class II-restricted epitope derived from unglycosylated MUC1. Using these mice, we have confirmed that adoptive transfer of MUC1-specific CD4+ T replaces the MUC1-specific T cell help that is missing in MUC1-Tg mice and restores their ability to respond to MUC1 vaccines. This work shows that the generation of CD4 helper T cell responses is critical to establishing effective immunity to MUC1+ cancers. |
